Ziprasidone mesylate is an atypical antipsychotic indicated for the treatment of acute agitation in schizophrenic patients for whom treatment with ziprasidone is appropriate and who need intramuscular (IM) antipsychotic medication for rapid control of agitation. Since there is no experience regarding the safety of administering ziprasidone IM to schizophrenic patients already taking oral ziprasidone, the practice of co-administration is not recommended.
In choosing among treatments, prescribers should be aware of the capacity of ziprasidone mesylate for injection to prolong the QT interval and may consider the use of other drugs first. Ziprasidone is contraindicated in patients with a known history of QT prolongation, in patients with recent acute myocardial infarction, in those with uncompensated heart failure, and in combination with other drugs that have demonstrated QT prolongation.
The generic product is available in a single-dose vial as ziprasidone mesylate (20mg ziprasidone/mL) when reconstituted. It is supplied in cartons containing 10 vials.
“We’re pleased to bring the first generic of Ziprasidone Mesylate for Injection to market for patients who will benefit from access to affordable medicine,” said Marc Kikuchi, CEO, North America Generics, Dr. Reddy’s Laboratories. “This is a great addition to our injectable offering in the US market as we continue to augment our portfolio and drive growth within the hospital segment.”
For more information visit drreddys.com.
This article originally appeared on MPR